Session » (0470–0505) Rheumatoid Arthritis – Treatment Poster I

Date: Sunday, October 26, 2025

Time: 10:30AM-12:30PM

Meeting: ACR Convergence 2025

10:30AM-12:30PM: Abstract Number: 0473

A Phase 2b Dose-Ranging Study of Peresolimab for Adults with RA

10:30AM-12:30PM: Abstract Number: 0471

An Open-label, Randomized, Controlled Phase 1/2 Study to Assess the Safety and Efficacy of KYV-101 Anti-CD19 CAR-T Cell Therapy in Active and Difficult-to-treat ACPA positive Rheumatoid Arthritis: Preliminary Results of the COMPARE Trial

10:30AM-12:30PM: Abstract Number: 0491

Association of Short Chain Fatty Acids and Diet with Disease Activity and Methotrexate Response in New Onset Rheumatoid Arthritis: A Proof of Principle Study

10:30AM-12:30PM: Abstract Number: 0477

At the patient level, ultrasound evaluation during the follow up of rheumatoid arthritis does not modify radiographic evolution: a prospective, multicenter, randomized, pragmatic clinical trial (BCD study)

10:30AM-12:30PM: Abstract Number: 0496

Certolizumab Pegol Shows a Higher Retention Rate Compared to JAK Inhibitors in Patients with Rheumatoid Arthritis, Regardless of Baseline Rheumatoid Factor Levels. A Multicenter Retrospective Study.

10:30AM-12:30PM: Abstract Number: 0470

Characterization of Patients With Rheumatoid Arthritis Based on Distinct Patterns of Pain Improvement Following Treatment With Filgotinib: A Post Hoc Analysis of FINCH 1

10:30AM-12:30PM: Abstract Number: 0484

Comparable Efficacy of FK-Tocilizumab and Reference Tocilizumab in Rheumatoid Arthritis Patients With and Without Prior Biologic Exposure

10:30AM-12:30PM: Abstract Number: 0472

Detrimental Effects of Umbilical Cord Blood-derived Mesenchymal Stem Cells Intra-articular Injections on Pannus Invasiveness

10:30AM-12:30PM: Abstract Number: 0475

Drug Discontinuation in Inflammatory Arthritis Following Mandatory Non-Medical Switching from Originator to Biosimilar in Quebec, Canada

10:30AM-12:30PM: Abstract Number: 0497

Drug Survival and Discontinuation Reasons of Eight Biological Disease-Modifying Antirheumatic Drugs in 1,182 Patients with Rheumatoid Arthritis: A Retrospective Study Using the Niigata Orthopedic Rheumatoid Arthritis Database (NOSRAD)

10:30AM-12:30PM: Abstract Number: 0488

Early and Sustained Improvements in Disease Activity and Patient-Reported Outcomes in Patients Treated with Filgotinib for Rheumatoid Arthritis: Up to 2-Year Interim Real-World Data From FILOSOPHY and PARROTFISH

10:30AM-12:30PM: Abstract Number: 0495

Effectiveness and Safety of Iguratimod with Background Methotrexate Therapy in Indian Patients with Rheumatoid Arthritis: A Randomized Double Blinded Placebo Controlled Study

10:30AM-12:30PM: Abstract Number: 0480

Efficacy and safety of tacrolimus and its serum concentration in patients with rheumatoid arthritis with inadequate response to methotrexate

10:30AM-12:30PM: Abstract Number: 0489

Efficacy and safety profile of JAK inhibitors in current practice in rheumatoid arthritis

10:30AM-12:30PM: Abstract Number: 0487

Efficacy of sarilumab in patients with rheumatoid arthritis of different disease activity at treatment initiation: a post-hoc analysis of a Phase 3 trial of sarilumab in Japan

10:30AM-12:30PM: Abstract Number: 0476

Impact of Comorbidity Burden on the Efficacy of, a Direct Interleukin 6 Inhibitor, Olokizumab: Real World Evidence

10:30AM-12:30PM: Abstract Number: 0503

Impact of Olokizumab on Pain in Rheumatoid Arthritis: a Meta-analysis

10:30AM-12:30PM: Abstract Number: 0490

Infection Risks Associated with Monotherapy and Combination Therapies Using Biological or Targeted – DMARD in RA: A Systematic Review and Network Meta-analysis

10:30AM-12:30PM: Abstract Number: 0481

Intracellular Methotrexate Polyglutamate Profiles Do Not Correlate with Early Clinical Response in Treatment-Naïve Rheumatoid Arthritis: A Prospective Study

10:30AM-12:30PM: Abstract Number: 0500

Is Methotrexate Tapering Possible In Stable RA? Clinical Observations of Methotrexate Tapering At Two Tertiary Care Centers

10:30AM-12:30PM: Abstract Number: 0494

LFD-200, an Antibody Drug Conjugate that Selectively Delivers a Glucocorticoid Payload to Immune Cells, Provides Sustained Anti-inflammatory Effects Without Systemic Toxicity in Non-human Primates

10:30AM-12:30PM: Abstract Number: 0485

Multicenter study on the use of Upadacitinib: Results in RA patients previously treated with Baricitinib

10:30AM-12:30PM: Abstract Number: 0499

Olokizumab Improves Patient-Reported Outcomes in Rheumatoid Arthritis MTX-IR and TNF-IR Patients up to 106 Weeks (Results from Clinical Phase III Program)

10:30AM-12:30PM: Abstract Number: 0492

Outcomes of Total Knee Replacement in Patients with Rheumatoid Arthritis: A National Inpatient Sample Database Analysis

10:30AM-12:30PM: Abstract Number: 0498

Pharmacokinetic Similarity of DRL_AB, a Proposed Biosimilar Abatacept (Orencia®): Results from a Randomized, Single Dose, Double-Blind, Parallel Arm, Comparative Pharmacokinetic Study in Healthy Subjects by the Intravenous Route.

10:30AM-12:30PM: Abstract Number: 0501

Phase 1b Study of SBT777101, an Engineered CAR-T-Regulatory Cell Product, in Patients With Rheumatoid Arthritis: Interim Demographics and Safety

10:30AM-12:30PM: Abstract Number: 0493

Phase I Trial in Participants with Rheumatoid Arthritis and Healthy Volunteers with CIT-013, a First in Class NETosis Inhibitor

10:30AM-12:30PM: Abstract Number: 0482

R-2487, a Synthetic Biology-Based Oral Immunotherapy, Promotes Treg-Mediated Immune Rebalancing and Reduces Disease Activity in Rheumatoid Arthritis Patients

10:30AM-12:30PM: Abstract Number: 0478

Racial and Ethnic Disparities in DMARD Use and in Medicare Part B-Covered Options Among Medicare Beneficiaries with Late-Onset Rheumatoid Arthritis

10:30AM-12:30PM: Abstract Number: 0502

Real-World Comparative Safety of Tocilizumab and Sarilumab in Rheumatoid Arthritis: A Multi-Center Observational Study

10:30AM-12:30PM: Abstract Number: 0474

Real-World Experience of Janus Kinase Inhibitors; Retention and Factors Associated with Discontinuation

10:30AM-12:30PM: Abstract Number: 0479

Risk of Arrhythmias Following IL-6 Inhibitor Use; A Pharmacosurvellience Study of FDA Adverse Event Reporting System (FAERS)

10:30AM-12:30PM: Abstract Number: 0483

Safety of JAK inhibitors (JAKi) in chronic inflammatory arthritis (CIA): an observational study

10:30AM-12:30PM: Abstract Number: 0486

Safety of sarilumab in more than 1000 patients with rheumatoid arthritis in Japan by age group: a post-marketing surveillance study

10:30AM-12:30PM: Abstract Number: 0504

Spatial profiling of gene signatures in synovial tissue informs treatment strategy for Rheumatoid Arthritis

10:30AM-12:30PM: Abstract Number: 0505

Use of Upadacitinib in Real-World Clinical Practice: Patient Characteristics and Glucocorticoid-Sparing Effect

« View all sessions from this meeting